Evaxion Biotech A/S

EVAX

US29970R2040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-09-20 EDT			5-day change	1st Jan Change
2.990 ^USD	-5.08%		-0.33%	-56.39%

09-18	Evaxion Biotech A/S - Special Call
09-17	European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Evaxion Biotech A/S

Evaxion Biotech A/S - Special Call	09-18
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading	09-17	MT
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	09-16	MT
Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01	09-16	CI
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	09-12	MT
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading	09-11	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading	09-09	MT
Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01	09-09	CI
European Equities Traded in the US as American Depositary Receipts Edge Lower Friday; Set to End Week Up 0.5%	08-30	MT
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading	08-28	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading	08-26	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	08-22	MT
European Equities Traded in the US as American Depositary Receipts Open Week Strong Monday Trading	08-19	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	08-15	MT
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	08-14	MT
Evaxion Biotech A/S, Q2 2024 Earnings Call, Aug 14, 2024	08-14
Earnings Flash (EVAX) EVAXION BIOTECH Posts Q2 Revenue $154,000, vs. Street Est of $50,000	08-14	MT
Evaxion Biotech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-14	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	08-13	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	08-12	MT
European Equities Traded in the US as American Depositary Receipts Climb Higher in Thursday Trading	08-08	MT
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01	08-08	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	08-07	MT
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	08-06	MT
European Equities Traded in the US as American Depositary Receipts Plunge in Monday Trading	08-05	MT

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-10-07 - LSX Nordic Congress

More about the company